E-Therapeutics Plc. (LON:ETXP) offers public market investors a unique opportunity to gain exposure to a proprietary, cutting-edge in silico drug discovery platform that has already attracted significant investment and has been fully operational since 2014. This second-generation platform has generated new chemical entities (NCEs) in several different disease areas and, under a new CEO, is on the cusp of commercial validation. The priority for the company is securing deals to provide external validation of this approach. e-Therapeutics’ strength is its discovery capability, particularly in complex disease; it also has six internal discovery projects with the prospect of more to come. The CEO’s business review will determine the focus of internal investment and business development activities.
The premise
e-Therapeutics carries out early discovery work in silico, structuring and analysing its proprietary disease networks using network science and computational optimisation to identify effective protein target sets and compounds with matching multi-point footprints. The principle is that this approach identifies biologically active lead compounds (>10% of candidates from the platform have the desired activity profile in phenotypic screens), which should improve drug discovery productivity and influence the probability of success downstream in Phase II and III trials.
To read the entire report Please click on the pdf File Below